You are here

INVOKANA® monotherapy demonstrated statistically significant reductions in body weight vs placebo at 26 weeks1,2

Secondary Endpoint: Adjusted Mean Change in Body Weight From Baseline (%)


Significant reductions in body weight: INVOKANA® monotherapy vs Placebo Significant reductions in body weight: INVOKANA® monotherapy vs Placebo

 

INVOKANA® is not indicated for weight loss.

Study Design

The efficacy and safety of INVOKANA®monotherapy was assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,2

Learn about SYSTOLIC BLOOD PRESSURE CHANGE

See the results of INVOKANA® VS JANUVIA®, VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.